Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.

IF 2.4 4区医学 Q3 NUTRITION & DIETETICS

Nutrition and Cancer-An International Journal Pub Date : 2025-01-01 Epub Date: 2025-09-02 DOI:10.1080/01635581.2025.2553381

Yinfan Wu, Yan Wu, Huiping Ding, Qiong Wang, Haiyan Han, Tianze Yu, Yiqin Pan, Yiqun Ling

{"title":"Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.","authors":"Yinfan Wu, Yan Wu, Huiping Ding, Qiong Wang, Haiyan Han, Tianze Yu, Yiqin Pan, Yiqun Ling","doi":"10.1080/01635581.2025.2553381","DOIUrl":null,"url":null,"abstract":"Malnutrition and sarcopenia may occur concurrently (Malnutrition-sarcopenia syndrome, MSS) in gastric cancer patients, affecting the prognosis and clinical outcomes. This study aimed to evaluate MSS prevalence and oral nutritional supplements (ONS) efficacy. This study included a retrospective analysis of 761 gastric cancer patients post-resection to assess MSS prevalence/prognosis, and a prospective non-randomized trial enrolled 81 MSS patients comparing ONS (500 kcal/day ×4 wk) versus standard care. In the retrospective cohort, MSS prevalence was 20.2%, and MSS independently predicted higher postoperative complication (OR: 2.330, 95% CI: 1.256-4.321, p = 0.007), recurrence/metastasis (OR: 4.162, 95% CI: 1.965-8.815, p < 0.001) and worse overall survival (HR: 1.649, 95% CI: 1.007-2.700, p = 0.047). In the prospective trial, ONS significantly improved weight maintenance compared to standard care (p = 0.032). Non-significant trends were observed in ONS group for shorter postoperative length of stay (PLOS) (6.8 vs 8.0 days), fewer complications (5.0% vs 22.0%) and improved handgrip strength (HGS) recovery (0.1 kg vs -0.9 kg). MSS is prevalent in gastric cancer and associated with adverse outcomes. ONS effectively preserves weight and shows recovery benefits, supporting its integration into MSS management.","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1132-1141"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and Cancer-An International Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01635581.2025.2553381","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Malnutrition and sarcopenia may occur concurrently (Malnutrition-sarcopenia syndrome, MSS) in gastric cancer patients, affecting the prognosis and clinical outcomes. This study aimed to evaluate MSS prevalence and oral nutritional supplements (ONS) efficacy. This study included a retrospective analysis of 761 gastric cancer patients post-resection to assess MSS prevalence/prognosis, and a prospective non-randomized trial enrolled 81 MSS patients comparing ONS (500 kcal/day ×4 wk) versus standard care. In the retrospective cohort, MSS prevalence was 20.2%, and MSS independently predicted higher postoperative complication (OR: 2.330, 95% CI: 1.256-4.321, p = 0.007), recurrence/metastasis (OR: 4.162, 95% CI: 1.965-8.815, p < 0.001) and worse overall survival (HR: 1.649, 95% CI: 1.007-2.700, p = 0.047). In the prospective trial, ONS significantly improved weight maintenance compared to standard care (p = 0.032). Non-significant trends were observed in ONS group for shorter postoperative length of stay (PLOS) (6.8 vs 8.0 days), fewer complications (5.0% vs 22.0%) and improved handgrip strength (HGS) recovery (0.1 kg vs -0.9 kg). MSS is prevalent in gastric cancer and associated with adverse outcomes. ONS effectively preserves weight and shows recovery benefits, supporting its integration into MSS management.

查看原文本刊更多论文

口服营养补充剂对胃癌营养不良-肌肉减少综合征患者的影响。

胃癌患者营养不良和肌少症可能同时发生（营养不良-肌少症综合征，MSS），影响预后和临床结局。本研究旨在评估MSS患病率和口服营养补充剂（ONS）的疗效。该研究包括对761例胃癌术后患者的回顾性分析，以评估MSS的患病率/预后，并进行了一项前瞻性非随机试验，纳入了81例MSS患者，比较ONS （500 kcal/day ×4 wk）与标准治疗。在回顾性队列中，MSS患病率为20.2%，MSS独立预测较高的术后并发症（OR: 2.330, 95% CI: 1.256-4.321, p = 0.007）和复发/转移（OR: 4.162, 95% CI: 1.965-8.815, p = 0.047）。在前瞻性试验中，与标准治疗相比，ONS显著改善了体重维持（p = 0.032）。ONS组术后住院时间（PLOS）较短（6.8天vs 8.0天），并发症较少（5.0% vs 22.0%），手部握力（HGS）恢复改善（0.1 kg vs -0.9 kg）。MSS在胃癌中普遍存在，并与不良后果相关。ONS有效地保持了重量，显示了恢复的好处，支持集成到MSS管理中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition and Cancer-An International Journal 医学-营养学

CiteScore

5.80

自引率

3.40%

发文量

172

审稿时长

3 months

期刊介绍： This timely publication reports and reviews current findings on the effects of nutrition on the etiology, therapy, and prevention of cancer. Etiological issues include clinical and experimental research in nutrition, carcinogenesis, epidemiology, biochemistry, and molecular biology. Coverage of therapy focuses on research in clinical nutrition and oncology, dietetics, and bioengineering. Prevention approaches include public health recommendations, preventative medicine, behavior modification, education, functional foods, and agricultural and food production policies.